InvestDashboard.com



Gilead Sciences, Inc. (GILD)



$65.38
52 Week Low
$68.55
2017-04-28 15:47:29 MDT
$103.1
52 Week High

Basic Info

Healthcare
Sector
Biotechnology
Industry
Nasdaq
Stock Exchange
United States
Country

Market Cap: $86,600,000,000Large Cap (Between $10B and $100B)
Analyst Recommendation:2.3Analysts say: Buy-. (1=Strong Buy, 5=Strong Sell)
Beta: 0.99 Low Volatility Stock (beta under 1). Stock will go up less when the market goes up, and go down less when the market goes down. Beta of 1 means stock would match the S&P 500 Index.

Fundamentals

ForwardPE: 8.77
5 Yr Est Growth: -4.70 %
Yield: 3.10%
PEG-Y Ratio: N/A
Unknown PEG-Y ratio

Technicals

% Above 50 DayMA: 1.65%
% Above 200 DayMA: -4.18%
GILD Performance 52 Weeks: -34.62%
S&P 500 Performance 52 Weeks: 13.50%
Mixed Trend. Short Term trend is up, but longer term trend is down. Currently beyond technical death cross because 50 Day MA is below 200 Day MA. Stock is closer to 52 Week Low than 52 Week High.
GILD underperforming S&P 500 by -48.12% the last 52 Weeks.

Profile

Gilead Sciences, Inc., incorporated on June 22, 1987, is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products include AmBisome, Atripla, Cayston, Complera/Eviplera, Descovy, Emtriva, Epclusa, Genvoya, Harvoni, Hepsera, Letairis, Odefsey, Ranexa, Sovaldi, Stribild, Truvada, Tybost, Vemlidy, Viread, Vitekta and Zydelig. The Company's areas of focus include HIV; liver diseases, such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection; hematology/oncology; cardiovascular, and inflammation/respiratory diseases. The Company had operations in more than 30 countries, as of December 31, 2016.

More Valuation

Price To Book: 4.57
Great Value. Low Price to Book means better value.
EV to EBITDA: 5.24
Great Value! A low EV to EBITDA ratio is great. Ideally, under 10. Under 17 is okay.

More Info

Field Value Average Comments
% Held By Insiders0.60% 17.28%Held by fewer than average Insiders.
% Held By Institutions83.40% 62.07%Institutional percentage greater than average. Institutional buying and selling can really move stock price.
Short % Of Float1.00% 07.02% Shorted percentage less than average percent. Is stock loved? Do traders and investors believe in the stock?
Debt to Equity1.36 1.08 More Aggressive Financing. Each industry has different Debt/Equity standard. Higher than 1 means company is taking on more leverage.
Profit Margin %44.43%-00.18% Profit Margin is better than the average! Good job.
Operating Margin %59.44%-05.28% Operating Margin greater than average percent. Good.
Return on Equity %70.11%-08.79% Return on Equity greater than average percent. Good.
Return on Assets %20.78%-01.29% Return on Assets greater than average percent. Good.
Revenue Per Employee $3,376,666.67 $883,096.70 More than average Revenue Per Employee. This stock (or industry) could be very efficient.
Price to Cash 7.53 5.52 Higher than average Price to Cash. Meaning that the company has a lower percentage of cash as a percent of price. Cash can be good to cushion company during hard times, and as a potential source for buyouts or investments. However, some activists want the cash to be used by a company to buy its own stock, or to increase their dividend, or to invest the money.
CPEGY Ratio N/A 2.26Unknown.

Quick Thoughts

PROS:
  1. Low Forward PE: 8.77

  2. Above Avg Yield: 3.10%

  3. Stock is Above Short Term 50DMA: 1.65%

  4. Price to Book is under 5: 4.57

  5. Better than average EV/EBITDA: 5.24

  6. Shorted less than average: 1.00%

  7. Profit Margin is positively good: 44.43%

  8. Operating Margin is positively good: 59.44%

  9. Return on Equity is positively good: 70.11%

  10. Return on Assets is positively good: 20.78%

CONS:
  1. Less than Average 5 Yr Est Growth: -4.70 %

  2. Stock is Below Long Term 200DMA: -4.18%

  3. Stock underperforming S&P 500 over last 52 weeks: -48.12%

  4. Price to Cash Ratio (7.53) is greater than average. Company has less cash as a percent of price than the average.


Headlines


Stock Chart


InvestDashboard.com GILD: Gilead Sciences, Inc.

This page updated Tue May 2 22:00:01 MDT 2017.